6-14-2011

Functionalized Nanoceria Composition for Ophthalmic Treatment [CIP]

Sudipta Seal  
*University of Central Florida*

Manas Haldar  
*North Dakota State University - Main Campus*

Sanku Mallik  
*North Dakota State University - Main Campus*

Swanand Patil  
*University of Central Florida*

Find similar works at: [https://stars.library.ucf.edu/patents](https://stars.library.ucf.edu/patents)  
University of Central Florida Libraries [http://library.ucf.edu](http://library.ucf.edu)

This Patent is brought to you for free and open access by the Technology Transfer at STARS. It has been accepted for inclusion in UCF Patents by an authorized administrator of STARS. For more information, please contact STARS@ucf.edu.

**Recommended Citation**

Seal, Sudipta; Haldar, Manas; Mallik, Sanku; and Patil, Swanand, "Functionalized Nanoceria Composition for Ophthalmic Treatment [CIP]" (2011). *UCF Patents*. 204.  
[https://stars.library.ucf.edu/patents/204](https://stars.library.ucf.edu/patents/204)
FUNCTIONALIZED NANOCERIA COMPOSITION FOR OPHTHALMIC TREATMENT

Inventors: Sudipta Seal, Oviedo, FL (US); Swanand D. Patil, Orlando, FL (US); Manas K. Haldar, Fargo, ND (US); Sanku Mallik, West Fargo, ND (US)

Assignee: University of Central Florida Research Foundation, Inc., Orlando, FL (US)

Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 392 days.

Applied No.: 12/147,759
Filed: Jun. 27, 2008

Prior Publication Data

Related U.S. Application Data
Continuation-in-part of application No. 11/412,665, filed on Apr. 27, 2006, now Pat. No. 7,727,559.
Provisional application No. 60/946,815, filed on Jun. 28, 2007.

Int. Cl.
A61K 9/14 (2006.01)
A61K 38/24 (2006.01)

ABSTRACT
The invention provides a composition comprising a plurality of nanoceria particles, a sufficient amount of at least one inhibitor of human carbonic anhydrase II associated with said plurality of nanoceria particles, and a pharmaceutically acceptable carrier containing said plurality of nanoceria particles with associated inhibitor. One preferred inhibitor of human carbonic anhydrase II comprises 4-carboxybenzene sulfonamide. The disclosed composition is useful in treatment of glaucoma.

13 Claims, 6 Drawing Sheets
FIG. 2
FIG. 4
FIG. 6
1  FUNCTIONALIZED NANOCERIA
2 COMPOSITION FOR OPHTHALMIC
3 TREATMENT

RELATED APPLICATION

This application claims priority from co-pending provisional application U.S. Ser. No. 60/946,815, which was filed on 28 Jun. 2007, and which is incorporated herein by reference in its entirety. This application is also a continuation-in-part of Ser. No. 11/412,065, filed on 27 Apr. 2006 and which is additionally incorporated herein by reference in its entirety.

STATEMENT OF GOVERNMENT RIGHTS

The investigation leading to this application was supported at least in part by a grant from the National Science Foundation. The government may, therefore, have some rights in the invention, as specified by law.

FIELD OF THE INVENTION

The present invention relates to the field of nanotechnology and, more particularly, to nanoceria particles which carry a medicinal drug.

BACKGROUND OF THE INVENTION

Countless individuals suffer from the ocular disease glaucoma. This condition describes a destruction of optic nerve cells and deterioration of eyesight as a result of increased intraocular pressure. The pressure is caused in part by a buildup of carbon dioxide in the eye. An enzyme that aids in the production of CO2 is human carbonic anhydrase II (hCAII). This Zn2+ containing metalloenzyme (FIG. 1) catalyzes the reversible hydration of carbon dioxide to bicarbonate and is commonly found in living organisms.

Sulfonamide compounds have been shown to selectively inhibit hCAII even at low concentrations. Therefore, inhibition of hCAII with sulfonamides constitutes one of the most physiological approaches for treatment of glaucoma. In 1958 Beasley et al. reported the in vitro binding of 4-carboxybenzene sulfonamide (CBS) to the carbonic anhydrase (CA) enzymes. Since then, many other hCAII inhibitors based on this moiety have been reported. A remarkable increase in the hCAII inhibition activity was observed for simple aliphatic esters of CBS. Also, it is now extensively documented that significant enhancement of CA inhibition can be achieved through coupling the primary recognition aromatic sulfonamide motif with secondary binding elements. The mechanism for inhibition of hCAII by CBS involves coordination of the sulfonamide group (as the anion) to the zinc atom in the active site of hCAII to form a complex in an exothermic reaction. In particular, the biologically active agent could comprise a medicinal drug and, particularly, an ophthalmically active drug, which could be an enzyme inhibitor. In this preferred embodiment of the invention, the nanoceria particles are made by a method comprising a reaction according to Scheme 1A, shown in FIG. 3. Moreover, the nanoceria particles associated with carboxyfluorescein are made by a method comprising a reaction according to Scheme 1B in FIG. 3.

SUMMARY OF THE INVENTION

With the foregoing in mind, in one embodiment, the present invention advantageously provides a composition comprising a plurality of nanoceria particles, a sufficient amount of at least one inhibitor of human carbonic anhydrase II associated with said plurality of nanoceria particles, and a pharmaceutically acceptable carrier containing said plurality of nanoceria particles with associated inhibitor. The at least one inhibitor of human carbonic anhydrase II preferably comprises 4-carboxybenzene sulfonamide. Preferably, the enzyme inhibitor is effective against human carbonic anhydrase II and the composition is used in treating an eye disease, particularly glaucoma, by contacting the eye with the composition.

The composition may also further comprise a detectable tag associated with the plurality of nanoceria particles. The skilled will recognize that the term “tag” indicates any atom or molecule which, when associated with the nanoceria, imparts a property which allows for tracking of the nanoceria during treatment. Tracking may be by any known method, for example, fluorescence responsive to ultraviolet light. In effect, the tag may be a fluorescent tag associated with said plurality of nanoceria particles and the fluorescent tag is preferably a fluorescein compound associated with said plurality of nanoceria particles, in particular, carboxyfluorescein.

Another preferred embodiment of the invention includes a method of treating a patient’s eye condition. The method comprises providing a composition containing a plurality of nanoceria particles associated with a drug and suspended in a pharmaceutically acceptable carrier, and contacting the patient’s eye with the composition.

In this embodiment, the drug preferably comprises an enzyme inhibitor and especially an inhibitor of human carbonic anhydrase. The eye condition comprises glaucoma and drug comprises 4-carboxybenzene sulfonamide. In the method, contacting the eye may be accomplished in any fashion known to the skilled but, typically would comprise a procedure selected from instilling, injecting, diffusing and combinations thereof.

Nevertheless, while this disclosure preferably comprises nanoceria compositions and treatments directed to eye con-
ditions and, particularly, to glaucoma, the invention includes
within its scope the concept of associating a drug with the
nanoceria particles as carriers. The range of drugs that can be
employed in the invention is rather broad and includes any
drug or pharmaceutical composition that can be complexed,
associated with or otherwise bound to the nanoceria particles
without significantly adversely affecting the biological activ-
ity of the drug.

BRIEF DESCRIPTION OF THE DRAWINGS

Some of the features, advantages, and benefits of the
present invention having been stated, others will become
apparent as the description proceeds when taken in conjunc-
tion with the accompanying drawings, presented for solely
for exemplary purposes and not with intent to limit the inven-
tion thereto, and in which:

FIG. 1 is a cartoon diagram showing the structure of human
carbonic anhydrase;
FIG. 2 depicts the molecular structure of (a) carboxybenzene
sulfonamide (CBS) and (b) carboxyfluorescein (CBF);
FIG. 3 depicts schemes for synthesis of functionalized
nanoceria; (A) for nanoceria-CBS; and (B) for nanoceria-
CBS-CBF, according to embodiments of the present inven-
tion;
FIG. 4 shows high-resolution XPS spectra for the function-
alized nanoceria particles at various conjugation steps; (a) O
Is scan for epichlorohydrin-functionalized nanoceria; (b) O Is
scan for the opened epoxide ring of epichlorohydrin; (c) O Is
scan for carboxybenzene sulfonamide-functionalized nanoc-
eria; and (d) C Is scan for carboxyfluorescein-functionalized
nanoceria;
FIG. 5 are images from confocal fluorescence microscopy
of (a) bare nanoceria and (b) nanoceria with fluorophores; and
FIG. 6 shows line graphs indicating the rate of hydrolysis
of 4-nitrophenyl acetate by hCAII, determined using absorb-
ance change at 400 nm, as a function of the nanoceria concen-
tration.

DETAILED DESCRIPTION OF THE PREFERRED
EMBODIMENT

The present invention will now be described more fully
hereininafter with reference to the accompanying drawings, in
which preferred embodiments of the invention are shown. Un-
less otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this invention
pertains. Although methods and materials similar or equiva-
ient to those described herein can be used in the practice or
testing of the present invention, suitable methods and mate-
rals are described below. Any publications, patent applica-
tions, patents, or other references mentioned herein are incor-
porated by reference in their entirety. In case of conflict, the
present specification, including any definitions, will control.
In addition, the materials, methods and examples given are
illustrative in nature only and not intended to be limiting.
Accordingly, this invention may be embodied in many differ-
ent forms and should not be construed as limited to the il-
ustrated embodiments set forth herein. Rather, these illustrated
embodiments are provided so that this disclosure will be
thorough and complete, and will fully convey the scope of the
invention to those skilled in the art. Other features and advan-
tages of the invention will be apparent from the following
detailed description, and from the claims.

The term "pharmaceutical composition" is used herein as
commonly known by those skilled in the art and generally
indicates a mixture containing ingredients that are compatible
when mixed and which may be administered to a patient or
biological system, whether human, animal or in vitro, in order
to treat a condition or disease. A pharmaceutical composition
may cause a degree of toxicity in the patient to whom it is
administered but, typically, it would be given in a dosage form
and/or amount that does not cause substantial harm to the
patient or biological system being treated. Examples of this
dichotomy would include pharmaceutical compositions for
cancer chemotherapy, which are more toxic for cancer cells
than for normal cells but, nevertheless, exert a level of toxicity
on the patient's normal cells during treatment. A pharmaceu-
tical composition may include one or more medicinal drugs,
which may or may not be prescription drugs. Additionally, the
pharmaceutical composition may include carriers, solvents,
adjuncts, emollients, expanders, stabilizers and other com-
ponents, whether these are considered active or inactive
ingredients. The skilled will readily understand that the exact
makeup of the composition will depend on the intended route
of administration to the patient, for example, a composition
intended for topical application to the skin will necessarily
contain different components than one intended for oph-
thalmic instillation. Guidance for the skilled in preparing
pharmaceutical compositions may be found in the U.S. Phar-
maceutica-National Formulary and other recognized treatises
in the science of pharmacy.

The figures illustrate the invention disclosed, which com-
prises inhibition of hCAII, a primary target enzyme for the
treatment of glaucoma. Nanoceria, a nontoxic nanoparticle,
was functionalized with hCAII inhibitors and was tested as a
potential ophthalmic drug delivery tool. We have found vari-
ous applications of cerium oxide nanoparticles in biotechnol-
ogy. It was found that treatment with nanomolar concentra-
tions of cerium oxide nanoparticles increases cell longevity
and protects the cells from damages caused by X-ray radia-
tion and reactive oxygen species (ROS). These previous
studies have revealed that nanoceria particles are nontoxic
and exhibit favorable biocompatibility.

Our studies related to use of nanoceria to protect the retina
from oxidative stress caused by reactive oxygen species
showed that the nanoparticles injected in the vitreous showed
efficacy far away in the retina. Moreover, the nanoceria's
uptake in

human lung fibroblast cells was shown to be faster than the
physical transport to the cell suggesting that these particles
have favorable diffusive properties. Therefore, a composition
of CeO2 nanoparticles was deemed as potentially very good
candidate for serving as transport agent for the inhibitors.
Since carbonic anhydrase II is a cytosolic enzyme, that is, it is
found in cellular cytoplasm, the inhibitor-functionalized
nanoceria were synthesized to allow easy entry into living
cells.

The first step was to choose a molecule that can attach to
the nanoceria and that can inhibit carbonic anhydrase. Car-
boxybenzene sulfonamide (CBS) (FIG. 2a) was the primary
choice on the basis of the literature data, where it is shown that
theses benzencesulfonamides can serve as inhibitors of car-
carbonic anhydrases and can possess favorable carboxyl groups
for attachment. It was hypothesized that binding these
molecules to the nanoceria would create an effective inhibitor
of carbonic anhydrase that can be transferred into the cytosol.
Additionally, we also decided to attach a tracking compound,
acarboxyfluorescein molecule (FIG. 2b), to visualize the cell
permeation property of the nanoparticles through a confocal
fluorescence microscope.

The attachment of carboxybenzene sulfonamide and car-
boxyfluorescein molecules to nanoceria was confirmed using

4

4

3
X-ray photoelectron spectroscopy (XPS). The formation of the fluorophore-functionalized nanoparticles was further established through confocal fluorescence microscopy. Finally, the derivatized nanoceria were tested as inhibitors of the recombinant hCAII enzyme. This was accomplished by observing the effect of nanoparticles on the rate of hCAII-catalyzed hydrolysis of the substrate 4-nitrophenyl acetate.26

Experimental Section

Functionalization of Cerium Oxide Nanoparticles (Scheme 1, FIG. 3).

Reaction of CeO2 Nanoparticles with Epichlorohydrin and Ammonia.

The 250 mg of cerium oxide nanopowder (obtained from Sigma-Aldrich Inc.) was suspended in 10 mL of 0.1 M NaOH solution for 5 min. Then, 5 mL of epichlorohydrin was added, followed by the addition of 0.5 mL of 2 M NaOH. The suspension was stirred at room temperature for 6-8 h. The reaction mixture was then centrifuged, and the supernatant was decanted. The nanoparticles were washed by water followed by centrifugation. This was done until the pH of the water was approximately 7.0. The nanoceria powder was then dried under vacuum. Next, the nanopowder was again suspended in water, 25 mL of 30% ammonium hydroxide solution was added, and the reaction mixture was stirred for 14 h. The product was purified by centrifugation, was washed with water, and was dried under vacuum again.

Reaction with Carboxybenzene Sulfonamide and Carboxyfluorescein.

The nanoparticles from the previous step were functionalized with the carboxybenzene sulfonamide and carboxyfluorescein molecules. These molecules (either 200 mg, 1 mmol of the CBS or carboxyfluorescein) were dissolved in 15 mL of dimethylformamide (DMF) and 5 mL of dichloromethane. Three hundred seventy-five microliters (3.5 mM) of N-methylmorpholine (NMP) was added followed by the addition of 442.5 mg (1 mmol) of the benzotriazol-1-yl-oxy-tris(dimethylamino) phosphonium hexafluorphosphate (BOP) reagent. The reaction mixture was stirred for 10 min at room temperature. The nanoparticles were then added. The mixture was stirred for approximately 20 h at room temperature. The reaction was stopped with 1 mL of water, and the mixture was centrifuged. It was then washed with DMF, water, and acetone three times each to get rid of the unattached carboxyfluorescein and finally was centrifuged. The nanoparticles were finally dried under vacuum.

The carboxyfluorescein-functionalized nanoparticles were taken through the same procedure to attach the additional CBS. This resulted in nanoparticles functionalized with carboxybenzene sulfonamide, as well as particles with both the CBS and carboxyfluorescein as shown in Scheme 1.

X-Ray Photoelectron Spectroscopy (XPS).

The surface functionalization chemistry of the nanoceria was examined using a 5400 PHI ESCA (XPS) spectrophotometer. The base pressure during the analysis was approximately 10−9 Torr, and Mg Kα X-radiation (1253.6 eV) at a power of 200 W was used. The instrument was calibrated using a standard gold sample with the binding energy at 84.0±0.1 eV for Au (4f7/2). All the samples were placed on a carbon tape. Any charging shift produced during the scanning was subtracted by using a binding energy scale with the baseline set at 284.6 eV for the C (1s). The XPS spectra were deconvoluted using PenkFit (version 4) software. The surface concentration of various conjugates was 158 evaluated from the integrated areas of the peaks corresponding to the respective conjugates.

Confocal Fluorescence Microscopy (CFM).

An Olympus 161 Fluoroview IX 81 confocal fluorescence microscope was used. Imaging was performed on prepared slides with nanoceria samples functionalized with carboxyfluorescein. The concentration of nanoceria was optimized to 1 mg/mL of water for imaging. The emission and excitation wavelengths for carboxyfluorescein were determined to be 520 and 480 nm, respectively.

Ultraviolet-Visible Spectrophotometry (UV-vis).

Cary 1E UV-vis spectrophotometer (UV-vis) from Varian Inc. was used to determine the inhibition potential of the nanoceria functionalized with the CBS. The enzyme activity was measured in 25 mM HEPES buffer, pH 7.0 at 25°C, containing 10% acetonitrile. The concentration of hCAII (obtained from Sigma-Aldrich Company) was kept constant at 1 mM for all the experiments. The concentration of the substrate 4-nitrophenyl acetate (in acetonitrile), was 1 mM for experiments carried out with varying concentrations of functionalized nanoceria and varied between 1 and 5 mM for the kinetic parameter determination studies with constant concentration of the functionalized nanoceria at 0.1667 mg/mL. The initial rates of 4-nitrophenyl acetate hydrolysis by hCAII were monitored spectrophotometrically, at 400 nm, using the Cary WinUV Kinetics application. The molar absorption coefficient, ε of 18 400 M−1 cm−1, was used to determine the concentration of 4-nitrophenolate formed by hydrolysis, as reported in the literature.27

The substrate concentration dependent kinetic data in the absence and presence of functionalized nanoceria inhibitors was presented in the form of double reciprocal plots and was analyzed according to the Michaelis-Menten equation to obtain the K酶 and Vmax values. The inhibitor binding constant, Ki, for the functionalized-nanoceria inhibitors was determined according to the following relationship:29

\[ K_i = \frac{K_m[I]}{K_m - K_m} \]

where, [I] is inhibitor (functionalized nanoceria) concentration; K酶 and Km are Michaelis constants in the absence and presence of the inhibitor, respectively.

Results

The expected functionalization of nanoceria was confirmed by XPS. The attachments of the epichlorohydrin linker, the inhibitor, and the fluorophore were established by examining the high-resolution C (1s) and O (1s) XPS spectra. The attachment of the fluorophore-functionalized nanoparticles was further confirmed by imaging using a confocal fluorescence microscope.

Functionalization Chemistry Using X-Ray Photoelectron Spectroscopy (XPS).

The carboxybenzene sulfonamide and carboxyfluorescein were conjugated by first attaching epichlorohydrin to the surface of nanoceria particles. This is a standard SN2 reaction where the oxygen atom of the nanoceria essentially replaces the chlorine atom of the epichlorohydrin.30 This results in an oxygen atom that bonds the cerium with the carbon of the epichlorohydrin as seen in the first reaction of Scheme 1.

In case of nanocrystalline cerium oxide, the O (1s) spectra contain two peaks corresponding to the mixed valence state of Ce (Ce³⁺ and Ce⁴⁺) present in its crystal lattice. The peak at 530.5 eV corresponds to Ce⁴⁺ while the higher binding
energy peak at about 532.20 eV corresponds to Ce$^{3+}$. The two additional peaks present in the spectra given in FIG. 4d demonstrate that the expected functionalization occurred. These peaks include the O (1s) line of the epichlorohydrin’s epoxy group at 533.30 eV and the O—C bond that connects the main part of the epichlorohydrin molecule to the cerium oxide at 534.10 eV. The high-resolution O (1s) XPS spectra thus indicate the successful attachment of the epichlorohydrin molecule to cerium oxide nanoparticles. The loading of epichlorohydrin on the ceria nanoparticles, calculated from the integrated areas of O peaks corresponding to epichlorohydrin to those for Ce$^{3+}$ and Ce$^{4+}$, was evaluated to be 3.18 mmol/gm of CeO$_2$.

Ammonia was then used to open up the epoxide ring ($\text{S}_2\text{C}$ reaction) on the epichlorohydrin molecule to form amine (—NH$_2$) and hydroxyl (—OH) groups available for further reactions (FIG. 4b, Scheme 1). The indication that this reaction occurred lies in the diminishment of the peak at 533.30 from FIG. 4a. The new peak at 533.00 eV in FIG. 4b corresponds to the newly formed —OH groups. However, FIG. 4b also confirms that the O—C bond that links the epichlorohydrin molecule bond to the nanoceria remained with the peak at 534.00 eV. Thus, the epichlorohydrin was still attached to the nanoceria and the epoxide ring opened as expected. The integrated area analysis of the peaks confirmed almost 100% ring opening for the epoxide group of the epichlorohydrin conjugated to the cerium oxide nanoparticles.

The nanoceria now possessed two functional groups that could be further functionalized by the carboxybenzene sulfonamide and carboxyfluorescein molecules. Both of them have carboxyl groups that can react to the available amine and hydroxyl groups from the opened ring of the surface-functionalized nanoceria (FIG. 2). The coupling reactions included standard peptide coupling reagents, N-methyl morpholine (NM) and benzotriazol-1-yl-oxy-tris(dimethylamino) phosphoronic hexafluorophosphoric (BOP). The reactions were conducted in dimethylformamide (DMF), a polar aprotic solvent that facilitates the coupling.

The attachment of the inhibitor, CBS, to the amine group was confirmed by the O 1s, XPS spectrum in FIG. 4c. The locations of all of the peaks essentially remained the same from the previous spectrum in FIG. 4b except for two additional peaks. These peaks at 531.13 and 531.70 eV correspond to the double-bonded oxygen atoms of the C—O and S—O bonds, respectively, that are part of the CBS. The XPS analysis thus indicated that the inhibitor bonded to the nanoceria particles. The loading yield determined from the deconvoluted peak areas was evaluated to be 3.14 mmol/gm of CeO$_2$ (98%).

Instead of the O 1s spectrum, the carbon (C 1s) spectrum was used to confirm the attachment of carboxyfluorescein, because this large molecule shielded many of the oxygen peaks seen in the previous oxygen spectra. FIG. 4d shows the various peaks present in the XPS spectra corresponding to the different C positions in the structure of the carboxyfluorescein functionalized ceria nanoparticles. It confirms that the fluorophore was also attached successfully to the ceria nanoparticles via epichlorohydrin linkage. The XPS peak analysis gave the surface concentration of the fluorophore to be 6.0 mmol/gm of CeO$_2$. The results of the high-resolution XPS spectra for all of the reactions are summarized in Table 1 of the Supporting Information (not shown but incorporated herein by reference; this material is available to the public free of charge via the Internet at http://pubs.acs.org a web site of The American Chemical Society).

Confocal Fluorescence Microscopy.
Further evidence that the fluorescent molecules bonded was presented in the confocal fluorescence microscopy images. As seen in FIG. 4, the carboxyfluorescein-functionalized nanoparticles were clearly visible under a confocal fluorescence microscope ($\lambda_{ex}$=480 nm; $\lambda_{em}$=520 nm) as green dots while the bare nanoceria resulted in images showing a blank background. An individual green dot represents a small agglomerate of the ceria nanoparticles (particle size: 10-20 nm) successfully functionalized with carboxyfluorescein. This further demonstrates that the fluorophores were attached to the nanoceria. The procedure for attaching these fluorescent molecules can be used in future studies to track the nanoceria as they are inserted into living cells. Future studies will involve inserting these particles in vivo and tracking their movement as they approach the expected locations of enzymes.

Inhibition Studies.
The final facet of the study involved determining whether the functionalized nanoceria inhibited the recombinant hCAII enzyme. This was accomplished by observing the effect of nanoparticles on the rate of hCAII-catalyzed hydrolysis of the substrate 4-nitrophenyl acetate. Essentially, the nanoparticles were mixed with a solution of the 4-nitrophenyl acetate and enzyme. The UV-vis spectrophotometer then measured the absorbance values at 400 nm as 4-nitrophenylacetate was hydrolyzed to form 4-nitrophenolate. The change in the absorbance values at different concentrations of nanoceria indicated the inhibiting effect of the conjugated nanoparticles.

The declining slopes in FIG. 6 reveal that, when the inhibitor-functionalized nanoceria bound to the active site of hCAII, the rate of formation of 4-nitrophenolate from 4-nitrophenyl acetate decreased. A decrease in the rate of its formation produced a solution that became tinted at a slower rate, which was represented by the decrease in the absorbance values as a function of time (see FIG. 6). hCAII’s activity declined with increased concentration of nanoceria, as indicated by the decreasing rate for the hydrolysis of 4-nitrophenyl acetate to 4-nitrophenolate. Bare nanoceria did not affect the rate of hydrolysis of 4-nitrophenyl acetate. When the inhibitor was paired with the fluorophore, the inhibition was better than with nanoceria functionalized only with CBS. The kinetic parameters (K$_m$, V$_{max}$, and K$_i$) for the functionalized nanoceria samples, determined using the double-reciprocal plots, are summarized in Table 1.

<table>
<thead>
<tr>
<th>inhibitor</th>
<th>K$_m$ (mM)</th>
<th>V$_{max}$ (mM mm)</th>
<th>K$_i$ (mg mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>no inhibitor</td>
<td>115.23 ± 1.36</td>
<td>3.02 ± 0.15</td>
<td>1.89 ± 0.16</td>
</tr>
<tr>
<td>nanoceria with inhibitor</td>
<td>125.40 ± 0.98</td>
<td>3.24 ± 0.08</td>
<td>1.09 ± 0.09</td>
</tr>
<tr>
<td>CBS</td>
<td>135.24 ± 1.10</td>
<td>3.12 ± 0.10</td>
<td>0.96 ± 0.09</td>
</tr>
</tbody>
</table>

Discussion
One of the emerging goals of nanotechnology is to functionalize inert and biocompatible materials to impart precise biological functions. Several hybrid organic/inorganic nanoparticles have been described for diagnostic or therapeutic use, including quantum dots, polymers, and magnetofluorescent nanoparticles. Although many coupling systems have been reported for polymeric nanoparticle con-
jugation with varying degrees of success, the coupling and functionalization of inorganic nanoparticles with biomolecules has only been carried out with a limited number of chemical methods. Niemeyer has written an elaborate review on usage of various coupling agents such as citrate, streptavidin, and various other complex linker molecules with amide and carboxylic acid end groups for coupling of inorganic nanoparticles (Au, Ag, ZnS, CdS, SnO₂, TiO₂, etc.) and biomolecules (proteins, DNA, etc.).

In this disclosure, we have shown the simultaneous conjugation of the hCAII inhibitor, CBS, and the fluorophore, carboxyfluorescein, to cerium oxide nanoparticles via epichlorohydrin as a linker molecule. Epichlorohydrin is a highly reactive compound used in manufacture of epoxy and phenox resin. It is also used as a solvent and in the synthesis of glycerol. Anirudhan et al. have developed a new adsorbent system for phosphate removal from wastewaters using epichlorohydrid to modify lignocellulosic residue. Also, it has been used in synthesis of lipopolyhydroxalkylamines for gene delivery. Weissleder et al. cross-linked the monocystalline magnetic nanoparticles, consisting of 3 nm core of (Fe₂O₃)ₙ(Fe₃O₄)ₘ covered with a layer of dextran, with epichlorohydrin and aminated them by reaction with ammonia to provide primary amine groups for the parallel synthesis of a library comprising 146 nanoparticles decorated with different synthetic small molecules. Similarly, in the present study, epichlorohydrin was attached to the ceria nanoparticles via a condensation reaction between the organochloride group from epichlorohydrid and the surface hydroxyl groups of the nanoceria particles and then was aminated to provide primary amine group for conjugation of enzyme inhibitor as well as the fluorophore to the nanoceria particles. The epichlorohydrid may have provided a spacer that allowed the inhibitor to reach the active site of the carbonic anhydrase and to reduce any steric hindrance of the enzyme’s interaction with the inhibitors on the surface of the nanoparticles. Furthermore, the inhibition was nearly directly proportional with increased concentration of the functionalized nanoceria inhibitors (FIG. 6). The analysis of the kinetic data confoned to the competitive type of inhibition model. Higher Kₘ values in the presence of functionalized nanoceria inhibitors than in its absence eliminate the possibility of “noncompetitive inhibition”. In conclusion, these results demonstrate that inhibition of the hCAII enzyme can be achieved using nanoceria particles functionalized with CBS.

The aim of the present application is to show that a successful conjugation of the ceria nanoparticles can be carried out using epichlorohydrid as a linker molecule and that such conjugated nanoparticles can be used for hCAII inhibition along with fluorescence-imaging capabilities. The inhibition results may be further enhanced using multiprong surface-binding groups. Our earlier studies in this regard have shown a potential strategy to improve inhibition of hCAII by attaching a surface-histidine recognition group to the inhibitor. Our ongoing investigations include the usage of the same conjugation process for multiprong inhibitors of hCAII for improved results.

CONCLUSION

Nanoceria were successfully functionalized and tested as inhibitors for hCAII. High-resolution XPS C 1s and O 1s spectra were effectively utilized to follow the necessary steps in the reaction process. The fluorescence microscope images and quantitative observations further confirmed that the carboxyfluorescein molecules bonded to the nanoceria particles. These results are very promising, and more studies will likely evolve into an inhibition of hCAII in living cells and an effective treatment of glaucoma and other diseases.

Furthermore, inhibitors for other disease associated enzymes can be immobilized on the nanoceria and then applied to the enzymes. The potential applications for functionalized cerium oxide nanoparticles seem limitless as a potential nontoxic drug delivery tool.

Accordingly, in the drawings and specification there have been disclosed typical preferred embodiments of the invention and although specific terms may have been employed, the terms are used in a descriptive sense only and not for purposes of limitation. The invention has been described in considerable detail with specific reference to these illustrated embodiments. It will be apparent, however, that various modifications and changes can be made within the spirit and scope of the invention as described in the foregoing specification and as defined in the appended claims.

That which is claimed is:

1. A composition comprising:
   - a plurality of nanoceria particles;
   - a sufficient amount of at least one inhibitor of human carbonic anhydrase II associated with said plurality of nanoceria particles; and
   - a pharmaceutically acceptable carrier containing said plurality of nanoceria particles with associated inhibitor.

2. The composition of claim 1, wherein said at least one inhibitor of human carbonic anhydrase II comprises 4-carboxybenzene sulfonamide.

3. The composition of claim 1, further comprising a detectable tag associated with the plurality of nanoceria particles.

4. The composition of claim 1, further comprising a fluoresein compound associated with said plurality of nanoceria particles.

5. The composition of claim 1, further comprising a fluororescin compound associated with said plurality of nanoceria particles.

6. The composition of claim 1, further comprising carboxyfluorescein associated with said plurality of nanoceria particles.

7. The composition of claim 1, wherein said enzyme inhibitor is effective against human carbonic anhydrase II and the composition is used in treating an eye disease by contacting the eye with the composition.

8. A composition comprising:
   - a plurality of nanoceria particles;
   - a sufficient amount of at least one biologically active agent bound to said plurality of nanoceria particles; and
   - a pharmaceutically acceptable carrier containing said plurality of nanoceria particles with bound inhibitor.

9. The composition of claim 8, wherein the biologically active agent comprises a medicinal drug.

10. The composition of claim 8, wherein the biologically active agent comprises an ophthalmically active drug.

11. The composition of claim 8, wherein the biologically active agent comprises an enzyme inhibitor.

12. The composition of claim 8, wherein the biologically active agent comprises a sulfonamide compound.

13. The composition of claim 8, wherein the biologically active agent comprises a sulfonamide compound that inhibits human carbonic anhydrase.

* * * * *